You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

First Combination Drug for Type 2 Diabetes and Hyperlipidemia

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000411172.23319.c3
Drug Watch

* Juvisync is the first approved fixed-dose combination drug to treat type 2 diabetes and hyperlipidemia. It combines the anti-hyperglycemic drug sitagliptin (Januvia) with the antilipid drug simvastatin (Zocor).

* Various dose combinations will be available.

Author Information

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2012 Lippincott Williams & Wilkins, Inc.